GSK Announces AREXVY, Its Respiratory Syncytial Virus Vaccine, Is Now Available At All Major U.S. Retail Pharmacies
Portfolio Pulse from Happy Mohamed
GSK plc (NYSE:GSK) has announced that its Respiratory Syncytial Virus Vaccine, AREXVY, is now available at all major retail pharmacies in the US. The vaccine is recommended for individuals aged 60 years and older and is expected to be covered by most Medicare and commercial insurance plans. The vaccine was approved by the FDA on May 3rd, 2023, and is the world's first vaccine for RSV for older adults.
August 17, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's AREXVY vaccine is now available at all major US pharmacies. This could potentially increase GSK's revenues as the vaccine is recommended for individuals aged 60 years and older, a significant demographic in the US.
The availability of GSK's AREXVY vaccine at all major US pharmacies increases its accessibility to the target demographic (individuals aged 60 years and older). Given that the vaccine is expected to be covered by most insurance plans, this could lead to increased uptake and potentially boost GSK's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100